Urocit-k and Melatonin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Urocit-k (potassium citrate) and Melatonin (melatonin). Common drug interactions include sinusitis among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Urocit-k and Melatonin. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Urocit-k?

Urocit-k has active ingredients of potassium citrate. It is often used in kidney stones. eHealthMe is studying from 708 Urocit-k users. Check the latest studies of Urocit-k.

What is Melatonin?

Melatonin has active ingredients of melatonin. It is often used in insomnia. eHealthMe is studying from 56,212 Melatonin users. Check the latest studies of Melatonin.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 20, 2026

20 people who take Urocit-k and Melatonin together, and have interactions are studied.

Urocit-k and Melatonin drug interactions.

What are the common drug interactions of Urocit-K and Melatonin, by gender? *:

female:

  1. Sinusitis (inflammation of sinus)
  2. Systemic mycosis (fungal infections of the body)
  3. Weight decreased
  4. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  5. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  6. Anxiety
  7. Bone density decreased
  8. Chronic kidney disease
  9. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  10. Cystitis (inflammation of the wall of the bladder)

male:

  1. Fatigue (feeling of tiredness)
  2. Alanine aminotransferase increased
  3. Sinus congestion (blockage of sinus)
  4. Blood electrolytes decreased
  5. Blood potassium decreased
  6. Bradycardia (abnormally slow heart action)
  7. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  8. Cervical vertebral fracture
  9. Confusional state
  10. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)

What are the common drug interactions of Urocit-K and Melatonin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Bone density decreased
  4. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  5. Chronic kidney disease
  6. Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
  7. Decreased activity
  8. Depression
  9. Emotional distress
  10. Fanconi syndrome acquired (self developed genetic disease of kidney damage due to defective transport system)

50-59:

n/a

60+:

  1. Fatigue (feeling of tiredness)
  2. Alanine aminotransferase increased
  3. Weight decreased
  4. Oral fungal infection
  5. Rotator cuff syndrome (a spectrum of conditions affecting the rotator cuff tendons of the shoulder)
  6. Sinus congestion (blockage of sinus)
  7. Blood electrolytes decreased
  8. Blood potassium decreased
  9. Bradycardia (abnormally slow heart action)
  10. Cervical vertebral fracture

What are the existing conditions these people have? *

  1. Immunodeficiency Common Variable: 8 people, 40.00%
  2. High Blood Cholesterol: 7 people, 35.00%
  3. Type 2 Diabetes: 5 people, 25.00%
  4. Sleep Disorder: 5 people, 25.00%
  5. Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 20.00%
  6. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 4 people, 20.00%
  7. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 20.00%
  8. High Blood Pressure: 4 people, 20.00%
  9. Parkinson's Disease: 3 people, 15.00%
  10. Pain: 2 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Urocit-k and Melatonin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Urocit-k and Melatonin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Urocit-k:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Melatonin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Urocit-k and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Melatonin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on potassium citrate and melatonin (the active ingredients of Urocit-k and Melatonin, respectively), and Urocit-k and Melatonin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: